We performed a dose escalation study on the six NSCLC cell lines with a PKA inhibitor H89 2HCL and a CDK2 inhibitor PHA-84812 to evaluate their effects on cell proliferation (Fig 6). This evidence concerns the gene CDK2 and non-small cell lung carcinoma.